Introduction
The disease progression of dilated cardiomyopathy (DCM) is highly diverse because of its aetiological and pathophysiological heterogeneity.
1 Recent clinical and experimental evidence has suggested that immune activation and the consequential inflammatory response in the myocardium may be involved in the process of deteriorating cardiac function, 2 -4 providing a rationale for immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy. 5 Some of the clinical investigations showed a favourable outcome resulting from immunosuppression, in particular for patients selected on the basis of their immunohistochemical histology. 6 -9 However, the utility of endomyocardial biopsy (EMB) to diagnose DCM is currently limited to only some medical facilities because of its lack of specificity and potential risk. 10 Thus, information obtained from EMB, if performed, seems generally underutilized in clinical practice for managing DCM.
Among the various kinds of immune-mediated cells, the activation of T lymphocytes and macrophages is believed to play a fundamental role in inadequately sustained myocardial inflammation. Extensive recent research has focused on macrophage differentiation and polarization in various diseases, such as cancers, autoimmune diseases, and infectious diseases. 11, 12 Macrophages are generally classified as either classically activated M1 or alternatively activated M2 macrophages. The M1 macrophages are known to have a proinflammatory phenotype that exhibits increased phagocytic activity and secretes proinflammatory cytokines such as tumour necrosis factor-, interleukin (IL)-1, IL-6, and reactive oxygen intermediates, whereas the M2 phenotype is characterized by polar opposite activity, producing anti-inflammatory, fibrogenic and angiogenic factors that resolve inflammation and induce collagenogenesis and angiogenesis. 13 Recently, macrophages with an alternatively activated M2 phenotype have shed new light on immune-inflammatory systems. The M2 macrophages, which express specific cell surface protein CD163, are known to govern functions at the interface of immunity in various organs such as the liver, lung and spleen.
14 We, and others, have previously reported that the expression of macrophages skewed toward M2 plays a vital role in the cardiac healing and remodelling process after myocardial infarction (MI). 15, 16 The M2 macrophages, with their profibrotic and anti-inflammatory properties, contribute to fibrotic replacement of the necrotic tissue essential for preventing the exacerbation of left ventricular (LV) remodeling. 17 However, in DCM, where tissue damage and fibrosis develop simultaneously, it is entirely unclear how the inflammatory cell infiltrates such as T cells and M1 and M2 macrophages function in the myocardium.
The purpose of this study was to clarify the impact of myocardial inflammatory cell infiltrates, especially focusing on macrophages, on long-term outcomes and myocardial fibrotic formation in patients with newly diagnosed DCM.
Methods

Study population
We screened patients admitted to our hospital with a diagnosis of heart failure with reduced ejection fraction who underwent diagnostic EMB for LV dysfunction between January 2005 and December 2009. Inclusion criteria for LV dilation and reduced contraction were LV ejection fraction (LVEF) ≤45% and LV diastolic diameter >117% of the predicted value calculated using the formula: 45.3 × (body surface area) 1/3 -(0.03 × age) -7.2. 18 Body surface area was calculated by the Du Bois formula: 0.007184 × weight 0.425 × height 0.725 . All patients underwent a detailed medical interview, physical examination, laboratory tests, echocardiography and cardiac catheterization. Coronary angiography, right heart catheterization and right ventricular (RV) EMB were performed for all patients. Exclusion criteria included ischaemic cardiomyopathy, hypertrophic cardiomyopathy, valvular heart disease, hypertensive heart disease, a history of uncontrollable or untreated hypertension for at least a year before the documentation of LV dysfunction, and other secondary cardiomyopathies such as sarcoidosis and amyloidosis. Also excluded were patients (i) with significant (>50%) coronary stenosis at the main branch, or (ii) with a history of malignant disease, cardiac surgery or acute myocarditis, active infectious disease or collagen disease, or (iii) who were on immunosuppressive medication. These exclusions ensured that the entire study cohort exhibited no clinical suggestion of inflammatory heart disease. Ultimately, a total of 182 patients were included in the study population.
Study protocol
The patients' basic clinical data were collected from their medical records, including age, sex, body mass index, presenting symptoms, blood pressure, heart rate, previous comorbid diseases, laboratory data [e.g. plasma brain natriuretic peptide (BNP), haemoglobin, and serum creatinine levels], medications, and the results of image tests such as echocardiography and cardiac catheterization. For the survival analysis, data were obtained from medical records or by direct inquiry by mail or phone. The primary endpoint was defined retrospectively as the incidence of cardiovascular death or heart transplantation. This study was approved by the Ethics Committee of our institution (#M25-105-2) and was conducted in accordance with the principles of the Helsinki Declaration.
Echocardiography
Echocardiographic parameters were measured according to the recommendations of the American Society of Echocardiography. 19 The LV end diastolic diameter, LV end systolic diameter, the thickness of the interventricular septum and posterior ventricular wall, and the left atrial diameter were obtained from M-mode or two-dimensional images of parasternal long-axis views. The LVEF was calculated using the Teichholz formula. The severity of mitral regurgitation was graded qualitatively (as none, trace, mild, moderate, or severe), as reported previously. 20 
Cardiac catheterization
All patients underwent diagnostic cardiac catheterization including RV EMB. Left ventriculography (LVG) was performed to measure LVEF in the 30 ∘ right anterior oblique view using the centre-line method. For the 51 patients (28%) unable to complete LVG because of renal insufficiency or increased LV end-diastolic pressure, LVEF was determined from the value obtained by echocardiography. Coronary angiography was performed in all patients to exclude ischaemic heart disease. Haemodynamic data were obtained, including heart rate, aortic pressure, LV end-diastolic pressure, pulmonary capillary wedge pressure, pulmonary artery pressure, right atrial pressure, and cardiac output. Cardiac output was determined using the basic thermodilution method. Three to five EMB specimens were taken from each patient's RV septum using a 7 Fr disposable bioptome (Technowood Co., Ltd., Tokyo, Japan). The specimens were immediately fixed with 10% buffered formalin, followed by embedding in paraffin for serial sectioning for standard and immunohistochemical staining.
antibodies were used as primary antibodies to detect each inflammatory cell infiltrate. Specifically, mouse monoclonal antibody against CD3 (N1580, 1/10; Dako, Glostrup, Denmark) was used for T lymphocytes, CD68 (M0814, 1/1000; Dako) was used for whole macrophages, and CD163 (ab74604, 1/10; Abcam, Cambridge, MA, USA) was used for M2 macrophages. Antibody detection and counterstaining with haematoxylin were performed using a Bond Polymer Refine Detection Kit (DS9800; Leica Biosystems). To exclude the possibility of false-positive responses from the secondary antibody or from non-specific binding of immunoglobulin G (IgG), mouse IgG1 antibody (X0931; Dako, Glostrup, Denmark) was substituted as a negative control for the primary antibodies against CD3, CD68, and CD163.
Counts of the myocardial inflammatory cell infiltrates and collagen area measurement
Whole-slide images were scanned with an Aperio Scan-Scope XT (Leica Biosystems), and digital slides were viewed using Aprio ImageScope software (Leica Biosystems). Photomicrographs were taken in five randomly selected high-power fields in a low-magnification whole-view of the digitized picture. The number of infiltrating CD3-, CD68-, and CD163-positive cells in the photomicrographs were counted by two pathologists (H.I.U. and K.O.O.) in a blinded manner. Positive cells in the vessels were excluded from the total count.
To ensure that positive inflammatory cells in the vessels had been adequately excluded, we performed double immunostaining using the ChromoPlex 1 Dual Detection Kit (Leica Biosystems, Newcastle upon Tyne, UK) with two separate colour developing systems (alkaline phosphatase and Fast Red substrate for CD3-red staining for inflammatory cells; peroxidase and diaminobenzidine substrate for CD34-brown staining for endothelial cells; see the Supplementary material online, Figure S1 ) in the representative six cases. The counts of the myocardial inflammatory cells with double immunostaining were comparable to those with single immunohistochemistry counterstained with haematoxylin, the method used in this study.
Myocardial collagen accumulation was semi-quantitatively measured in Masson's trichrome-stained sections, as described previously. 21 Collagen area fraction (CAF) was determined automatically by ImageJ software (National Institutes of Health, Bethesda, MD, USA) as the ratio of the total blue-stained area to the whole myocardial area.
Statistical analysis
The analyses were performed using SPSS Statistics version 23.0 (IBM Corp., Armonk, NY, USA). All quantitative data were expressed as mean ± SD. The statistical significance of differences was analysed using the unpaired Student's t-test for parametric continuous variables and the Mann-Whitney U-test for non-parametric continuous variables. Categorical variables were compared using Fisher's exact test. Receiver operating characteristic curves were constructed to determine cut-off values. The primary endpoint was cardiovascular death, heart transplantation, or the day of the final visit to the hospital. Event-free survival curves were constructed using the Kaplan-Meier method, and the statistical significance of differences between curves was assessed using the log-rank chi-square statistic. Cox proportional hazard analyses for myocardial inflammatory infiltrates were performed with clinical variables that are generally recognized to be parameters that influence heart failure prognosis. performed to determine the factors that were significantly associated with CAF. After univariate screening, candidate variables with a value of P < 0.05 were entered into a multivariate model to identify independent predictors of CAF. Values of P < 0.05 were considered statistically significant.
Results
Patients
Baseline demographic, laboratory, echocardiographic and haemodynamic characteristics are shown in Table 1 . At discharge, 88% and 84% of the patients were receiving -blockers and angiotensin-converting enzyme inhibitor (ACE-I)/angiotensin II receptor blocker (ARB), respectively, suggesting that most patients were under optimal medical therapy for heart failure during the follow-up period. Mineralocorticoid antagonist and loop diuretics were administered to 49% and 64% of patients, respectively. Among the 182 patients enrolled in this study, 29 (16%) reached the primary endpoint of cardiovascular death or heart transplantation during the observation period of 6.9 ± 2.4 years.
Myocardial CD3-, CD68-, and CD163-positive cell infiltrates
Representative high-power field photomicrographs of immunohistochemistry and the distribution of the numbers of inflammatory infiltrates are shown in 
Patients' characteristics by infiltrating inflammatory cells
For each type of inflammatory cells, the patients were divided into two groups according to whether their cell counts were greater than or less than the cut-off value, and their baseline characteristics were compared (see the Supplementary material online, Table S1 ). No significant differences were observed at the diagnosis of DCM between high-count and low-count inflammatory cell groups, except that patients with high numbers of CD3-positive cells were younger, and those with high numbers of CD68-positive cells showed a greater frequency of being classified as New York Heart Association (NYHA) class III or class IV and had lower serum sodium levels. Hypertension history was more common in patients with low numbers of CD3-and CD163-positive cells. The LVEF, plasma BNP, and haemodynamic parameters did not differ 
Clinical outcome
Kaplan-Meier survival curves demonstrated that counts of myocardial inflammatory cells above the cut-off values were associated with poor long-term outcome in terms of cardiovascular death and heart transplantation (log-rank, CD3-positive ≥14 cells/mm 2 , P = 0.007; CD68-positive ≥32 cells/mm 2 , P = 0.011; CD163-positive ≥ 10 cells/mm 2 , P = 0.022; Figure 2) . A task force of the World Heart Federation (WHF) has defined inflammatory DCM as DCM with the presence of 14/mm 2 or more of infiltrating T-lymphocytes (including up to 4 macrophages/mm 2 ) in immunohistochemically stained EMB samples; this definition was endorsed by a recent position statement on myocarditis by the European Society of Cardiology. 22 Out of the 182 patients, 82 (46%) were diagnosed with inflammatory DCM according to these criteria. These patients experienced a poorer outcome (log-rank, P = 0.024; see the Supplementary material online, Figure  S2 ), despite having similar baseline characteristics apart from a higher rate of patients classified as NYHA class III or class IV and a lower prevalence of hypertension (P = 0.009 and P = 0.020, respectively; see the Supplementary material online, Table S2 ).
Multivariate Cox proportional hazard regression analyses revealed that a count for CD163-positive greater than the cut-off value (≥10/mm 2 ) was a predictive factor for poor outcome using either an unadjusted or adjusted model (hazard ratio 1.77, 95% confidence interval 1.19-2.62, P = 0.004, multivariable adjusted model; Table 2 ); however, this was not the case for CD3-or CD68-positive cells.
Collagen area fraction
Two patients were excluded from the CAF analysis because of inappropriate Masson's trichrome staining for the measurement. The CAF measured by Masson's trichrome staining for the other 180 patients ranged from 2.7% to 39.8% (mean ± SD, 15.1 ± 6.8%); Figure 3 shows the distribution. A cut-off value for a CAF of 18% was determined from receiver operating characteristic analysis, which maximized sensitivity and specificity; a CAF greater than this cut-off was related to a poor outcome (Figure 4) . The CAF was not significantly correlated with infiltrative count of CD3-or CD68-positive cells (see the Supplementary material online, Figure S3 ). However, it did show a positive correlation with the count of CD163-positive cells (r = 0.32, P < 0.0001; Figure S3) . Multivariate linear regression analysis demonstrated that the count of CD163-positive cell infiltrates was an independent determinant of CAF (p < 0.001) ( Table 3) .
Discussion
In the present study, we demonstrated that DCM patients with increased inflammatory cell infiltration into the myocardium, measured using immunohistochemical staining sections of RV EMB biopsy samples, had a worse long-term outcome. Both T-lymphocytes and macrophages had a significant impact on the prognosis of DCM. In addition, the anti-inflammatory M2 macrophage count, represented by CD163-positive infiltrates, was an independent determinant of cardiac fibrosis and was associated with a worse long-term outcome.
Owing to its pathogenic diversity, the disease progression of DCM varies greatly between individuals. Medications such as ACE-Is and -blockers are currently used to reduce morbidity and mortality in clinical heart failure, mostly with the aim of reducing neurohormonal or sympathetic activation. However, regardless of what the optimal therapy is, a considerable proportion of patients with DCM currently end up with their condition deteriorating to death or until they receive a heart transplant. Myocardial immune activation and concurrent inflammation have been considered as other factors that influence the progression of LV dysfunction in DCM. Several kinds of inflammatory infiltrates, represented by T cells and macrophages, have been identified in EMBs and autopsied hearts of DCM patients. 23, 24 A pathological study identified myocarditis, according to the classical Dallas criteria, in approximately 10% of DCM cases in a large series from a prospective study. 25 In addition, up to 50% of DCM patients could be diagnosed with inflammatory DCM, according to recent WHF criteria, by immunohistological analysis methods using antibodies to characterize the type of inflammatory infiltrates. 8, 26 Our finding that 46% of patients fulfilled these criteria was consistent with these previous reports and supports the idea that a considerable number of DCM patients could be exposed to myocardial immune activation that has a potential influence on deteriorating LV function. A more recent consensus statement of the European Society of Cardiology has proposed the following criteria for an inflammatory infiltrate: ≥14 leucocytes/mm 2 Although this was not identical to the criteria we adopted, we believe the difference would not influence the fundamental results of our study because T-lymphocytes play major roles in the pathogenesis of inflammatory DCM. It is noteworthy that, while myocarditis determined with the Dallas criteria had a similar prognosis to idiopathic DCM, patients with increased immune activity determined by immunohistopathology showed a poorer prognosis. 3 The present study also revealed the close association of infiltrative CD163-positive M2 macrophages with cardiac fibrosis, as well as a poor clinical outcome. CD163 has previously been reported to be a useful specific marker for M2 macrophages.
14
In addition, CD163-expressing macrophages are known to have regulatory functions at the interface of immunity in various organs such as the liver, lung and spleen, which has also been shown in EMB samples. 27, 28 In the present study, multivariate regression analysis demonstrated that the number of myocardial-positive CD163 infiltrates was an independent determinant of CAF among the variables that influence the disease course of heart failure. This finding may be associated with profibrotic capacity producing extracellular matrix components with alternatively activated M2 macrophages. Compared with classically activated M1 macrophages, the M2 phenotype is characterized by polar opposite activity, producing anti-inflammatory, fibrogenic, and angiogenic factors that resolve inflammation and promote fibrosis. 13 Indeed, the production of fibrosis-inducing cytokines such as transforming growth factor-may be a potentially important profibrotic aspect of M2 macrophages. 29 We have previously reported that cardiac M2-polarized macrophages, induced by the stimulation of IL-10, favoured reparative collagen deposition in the vulnerable infarct region after MI. 15 Our finding that M2 macrophages were closely associated with CAF and a poor outcome in patients with DCM is inconsistent with the situation post-MI. We speculate that this inconsistency may result from a difference in local or diffuse myocardial injury. That is to say, whereas fibrosis occurring in the post-MI phase is reparative in order to maintain cardiac structure with the vulnerable myocardium of necrotic tissue, collagenogenesis during ventricular remodelling in DCM is mainly reactive and promotes deterioration of the failing myocardium. Conversely, CD3-positive T cells and CD68-positive macrophages have pro-inflammatory profiles that are much more prone to myocardial damage than to repair; 30 it would therefore be expected that they would have no significant correlation with CAF. Our finding that both pro-inflammatory and anti-inflammatory infiltrates were associated with poor prognosis in DCM patients leads to some profound pathophysiological implications regarding the disease progression of cardiomyopathy. Intraperitoneal administration of CVB to certain mouse strains resulted in the development of chronic myocarditis with the sustained persistence of an intramyocardial inflammatory cellular response concomitant with LV dilatation and reduced function. 32 The continued inflammatory response and fibroblast mobilization that subsequently causes fibrosis without viral replication in a later phase of the CVB-induced myocarditis model suggests the possibility of virus-induced anti-cardiac autoimmunity against damaged myocardial proteins. 33 Although it remains controversial, several recent studies have favoured the view that the presence of virus genomes is of no prognostic relevance to patients with DCM. 3, 34, 35 In addition, an organ-specific autoimmune disease may, without any viral infection, trigger sustained myocardial inflammation in cardiomyopathic patients. 36 Regardless of the trigger of myocardial inflammation, the subsequent immune activation accompanied by a persistence of myocardial inflammatory infiltrates may be a causative factor of the deterioration in inflammatory DCM. Background characteristics were similar between patients with and without inflammatory infiltrates in the present study. This indicates that EMB seems to be necessary in order to identify the DCM patients with poor prognosis, possibly because of increased immunity, and to provide possible therapeutic selection according to the degree of inflammatory cell infiltration into the myocardium in patients with DCM. Oral prednisone therapy for DCM has been tested in a randomized placebo-controlled study, with negative results. 37 However, in a subset of patients with increased fibroblasts or lymphocytes, immunosuppression with prednisone showed beneficial effects on long-term outcome. Another study of immunosuppressive therapy with steroids and azathioprine demonstrated improved 2-year LV remodelling in patients with inflammatory DCM diagnosed by immunohistochemistry. 8 Based on these and other studies, recent position papers have recommended immunosuppressive therapy for non-infectious biopsy-proven inflammatory DCM. 22, 36 The present study has raised the possibility that immunostaining of CD3, CD68, and CD163 with EMB samples may help to stratify potential candidates for immunosuppressive therapy.
. Figure 4 Survival curve for cardiovascular death or heart transplantation according to collagen area fraction (CAF). The high CAF (≥18%) group had a significantly lower survival rate compared with the low CAF (<18%) group.
Limitations
There were several limitations to this study. First, because it is a retrospective, single-centre study, prospective multicentre investigations will be needed to confirm and build on the findings of the present study. Second, we were unable to perform molecular analyses to detect the presence of virus genomes because the only tissues available for this study population were the stored paraffin-embedded tissues. A prospective study that collects both fixed and fresh myocardial samples will be needed to clarify the impact of the presence of viruses in inflammatory DCM. Third, as myocardial inflammation may occur in a diffuse or focal manner, tissue collection by EMB yields the possibility of sampling error. However, we used a transcatheter method to obtain samples from three to five different sites in the RV septum to mitigate any sampling error. In addition, using immunohistochemistry together with routine histology may increase the sensitivity of EMB. Lastly, surface markers of inflammatory cells might not represent the entirety of specific cell types. The antibodies we used were CD3 for T lymphocytes, CD68 for whole macrophages and CD163 for M2 macrophages, which are widely used with reliability in clinical and experimental settings.
Conclusion
Increased myocardial immune activation in the myocardium was associated with poor long-term outcomes in patients with DCM. Increased collagen formation was strongly associated with M2 macrophage infiltration, suggesting that phenotypic polarization of macrophages toward M2 in the myocardium may contribute crucially to fibrotic ventricular remodelling in the disease process of DCM.
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Additional Supporting Information may be found in the online version of this article: Figure S1 . Representative microscopic section of an endomyocardial biopsy sample double immunostained with two separate colour developing systems counterstained with haematoxylin. substrate. Positive inflammatory cells in the vessels were excluded from the total count. Figure S2 . Survival curve for cardiovascular death or heart transplantation according to the presence of inflammatory dilated cardiomyopathy (DCM) as defined by the World Heart Federation criteria. The Kaplan-Meier method demonstrated a significantly lower survival rate for inflammatory DCM. Figure S3 . Correlation plots between collagen area fraction (CAF) and the counts for myocardial CD3-(A), CD68-(B) and CD163-(C) positive infiltrates/mm 2 . A positive correlation (r = 0.32, P < 0.001) was observed between CAF and the number of myocardial CD163-positive cells, whereas no significant correlation was seen between CAF and the numbers of myocardial CD3-or CD68-positive cells. Table S1 . Baseline characteristics of the study population according to the counts of myocardial inflammatory infiltrates. Table S2 . Baseline characteristics of the study population according to the presence of inflammatory DCM as defined by WHF criteria.
